Esperion Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
All right. Hello, everybody. Thanks for joining us at the Needham Virtual Health Care Conference. My name is Chad Messer. I'm a senior biotech analyst here at Needham & Company. It is my pleasure to be speaking today with Tim Mayleben, CEO of Esperion, to discuss progress at the company. And I think we're just going to jump right into it.
So good morning, Tim. I really want to start by congratulating Esperion for your execution over the last year. I mean we're in a global pandemic, but you guys launched 2 drugs. You delivered a Japanese deal, debt financing. How have you guys managed so well in this challenging environment?
Well, Chad, so first off, I just want to thank you for -- well, for you and your colleagues here at Needham for hosting us today. As you highlighted, 2020 was not the year any of us expected it to be. But I think one thing that has driven us for, well, most of the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |